Endometrial Thickness and Cancer: What’s the Connection?

A thicker-than-expected endometrial lining, typically measured on transvaginal ultrasound, is one of the earliest clues doctors use to flag possible endometrial cancer, but the relationship is far less straightforward than a single number on a screen might suggest. Endometrial thickness is a screening marker, not a diagnosis. Most women with a thickened lining do not have cancer, and a small but clinically significant number of women with cancer have a thin lining that looks reassuringly normal. Understanding what the measurement actually tells you, where it breaks down, and what happens next is more useful than fixating on a single cutoff number.

Why the Endometrium Thickens in the First Place

The endometrium is the inner lining of the uterus, and it is one of the most hormonally responsive tissues in the body. During reproductive years, it builds up each menstrual cycle under the influence of estrogen, then sheds during a period after progesterone levels drop. That cycle keeps thickness in check. After menopause, when menstruation stops and hormone levels change, the lining typically thins out and stays thin.

Trouble begins when estrogen stimulates the endometrium without adequate progesterone to counterbalance it. This “unopposed estrogen” is the central driver of most endometrial thickening that warrants medical attention. Endometrial cancer is clearly a hormonally responsive tumor, with estrogen unopposed by progestins playing a critical role.¹ Over time, chronic unopposed estrogen can push the lining through a spectrum of changes, from simple overgrowth (hyperplasia) to precancerous changes to frank cancer.²

The Cutoff Numbers Doctors Use

For postmenopausal women who experience vaginal bleeding, a widely used threshold is an endometrial thickness of 4 to 5 mm. A large meta-analysis of 31 studies found that using a 5 mm cutoff caught about 96% of endometrial cancers while sparing roughly half of women from unnecessary invasive testing, compared to lower thresholds of 3 or 4 mm that had similar sensitivity but flagged far more women for biopsy.³ That 5 mm threshold has become a standard triage point: if your lining measures below it, the chance of cancer is low enough that many doctors will monitor rather than biopsy immediately.

For premenopausal women, the picture is messier because the lining naturally fluctuates throughout the menstrual cycle. A study of premenopausal women with abnormal bleeding found that an 8 mm cutoff provided reasonable sensitivity and specificity, and a lining at or below that threshold was unlikely to harbor malignant pathology.⁴ A separate study in premenopausal women with abnormal uterine bleeding identified a slightly higher optimal cutoff of 9 mm, which had a negative predictive value of nearly 98%, meaning that when the lining measured 9 mm or less, cancer was effectively ruled out in that population.⁵ The positive predictive value, though, was modest, meaning that most premenopausal women with a lining above the cutoff still did not have cancer.

These cutoffs are useful for ruling cancer out, not for ruling it in. A thick endometrium gets you to the next step of evaluation. It does not, by itself, mean cancer is present.

When Thickness Is Found Without Bleeding

Sometimes a thick endometrial lining turns up incidentally on an ultrasound done for another reason, in a woman with no vaginal bleeding at all. This is a common scenario and a common source of anxiety. The clinical approach here is more conservative than it might seem. Current guidance suggests that for postmenopausal women without bleeding, routine endometrial sampling should not be automatically performed just because the lining looks thick. The decision is made case by case, considering individual risk factors such as obesity, diabetes, and tamoxifen use.⁶

A cohort study of nearly 500 asymptomatic postmenopausal women with thickened endometria found that about 2% had endometrial carcinoma. In that study, the thickness measurement itself had no independent predictive value for cancer. The only factor that independently predicted cancer was the presence of blood flow signals within the endometrial lesion on Doppler ultrasound.⁷ That finding is worth noting: in women without symptoms, thickness alone is a weak predictor, and additional imaging features like abnormal blood flow patterns matter more for deciding who actually needs a biopsy.

What Else Causes a Thick Lining Besides Cancer

Most thick endometria are not cancerous. The more common causes include endometrial polyps, simple hyperplasia without concerning cellular changes, and submucosal fibroids. In postmenopausal women, even cystic atrophy can mimic a thickened lining on ultrasound. Research on ultrasound patterns has shown that certain appearances help distinguish these conditions. Cystic spaces within the endometrium, for instance, are strongly predictive of polyps rather than cancer, while a heterogeneous, irregular appearance is more associated with carcinoma.⁸

This means the ultrasound pattern matters alongside the thickness measurement. A uniformly thickened, smooth lining with small cysts suggests a polyp. A thickened, irregular, heterogeneous lining with abnormal blood flow raises more suspicion for cancer. Neither pattern gives a definitive answer on its own, but together they help doctors decide how urgently to pursue tissue sampling.

Major Risk Factors That Drive Thickening and Cancer

Several conditions create the kind of prolonged, unopposed estrogen exposure that promotes both endometrial thickening and cancer risk.

Obesity: Fat tissue converts androgens into estrogen through a process called aromatization. Obese women face roughly two to four times the risk of developing endometrial cancer compared to women at a normal weight, driven by this chronic estrogen production plus insulin resistance and inflammation.⁹
Polycystic ovary syndrome: PCOS causes chronic anovulation, meaning ovulation does not occur regularly. Without ovulation, the body does not produce the cyclical progesterone that normally keeps endometrial growth in check, resulting in prolonged unopposed estrogen exposure.¹⁰
Estrogen-only hormone therapy: Taking estrogen replacement without a progestin after menopause is a well-documented risk factor. When progestins are added continuously, the risk of endometrial cancer actually drops. But sequential regimens, where progestin is only taken part of the month, still carry elevated risk.¹¹

The Tamoxifen Complication

Tamoxifen, widely used for breast cancer treatment and prevention, creates a uniquely confusing situation for endometrial screening. The drug acts like an anti-estrogen in breast tissue but behaves like an estrogen in the uterus, stimulating the endometrial lining. Women taking tamoxifen often develop a characteristic “Swiss cheese” pattern on ultrasound, with a thickened endometrium full of cystic spaces that can look alarming but often represent benign changes like polyps or cystic atrophy.¹²

The endometrial thickening gets worse the longer tamoxifen is used. In one study, women on tamoxifen for fewer than five years had a median endometrial thickness of 5 mm, while those on it for five years or longer had a median of 14 mm. The rate of abnormal biopsy findings climbed from 44% to 58% with longer use, and the two endometrial cancers in that study occurred in women who had been on tamoxifen for six years.¹³ A more recent study confirmed that roughly 12% of breast cancer patients on tamoxifen developed endometrial hyperplasia, and about 4% developed endometrial cancer, with women who had pathological findings showing significantly thicker endometria.¹⁴

The practical problem is that the standard thickness cutoffs designed for women not on tamoxifen do not work well here. The drug makes the endometrium thicker across the board, so using a 5 mm threshold would flag nearly every woman on long-term tamoxifen for biopsy. Doctors managing these patients rely more heavily on symptoms like bleeding, Doppler blood flow patterns, and individual risk assessment than on thickness alone.

When Thin Does Not Mean Safe

Perhaps the most important limitation of endometrial thickness as a screening tool is that some aggressive forms of endometrial cancer can develop even when the lining looks thin. The common type of endometrial cancer, called endometrioid carcinoma, is estrogen-driven and typically does cause the lining to thicken. But rarer, more aggressive subtypes like uterine serous carcinoma develop through different biological pathways and do not depend on estrogen-driven thickening.

Research has found that nearly 25% of patients with uterine serous carcinoma who had a transvaginal ultrasound showed an endometrial lining of 4 mm or less. If ultrasound were the only triage tool, one in four of these patients would potentially experience a delayed diagnosis.¹⁵ Another study found that in cases of aggressive (type 2) endometrial cancers, 17% had a lining measuring under 4 mm, and another 17% had an indistinct lining that could not be reliably measured at all. Every one of these patients with a non-thickened lining had other ultrasound abnormalities like fluid in the uterine cavity, a myometrial mass, or an enlarged uterus.¹⁶

A recent retrospective study comparing endometrioid and non-endometrioid cancers in women with postmenopausal bleeding found that about 5.5% to 6% of cancers in both groups had a false-negative thin endometrium at or below 4 mm, with no significant difference between cancer types.¹⁷ The takeaway is that symptoms like postmenopausal bleeding deserve investigation regardless of what the endometrial thickness shows.

Racial Disparities in How Well Thickness Screening Works

A growing and troubling body of research shows that the standard endometrial thickness cutoffs do not perform equally well across racial groups. A simulation study estimated that among Black women, the commonly recommended 4 mm threshold caught fewer than half of endometrial cancers, with a sensitivity of only about 48%. Among white women evaluated with the same cutoff, sensitivity was roughly 88%.¹⁸ That is an enormous performance gap for a screening tool assumed to work the same way for everyone.

Part of this disparity comes from the higher prevalence of uterine fibroids in Black women, which can make it physically difficult to visualize the endometrial lining on ultrasound. One study found that Black women had significantly lower rates of completed transvaginal ultrasound exams compared to white women, but that disparity disappeared when women with fibroids were excluded from the analysis.¹⁹ Another study directly examining Black patients with endometrial cancer found that at the standard 5 mm threshold, there was an 11% probability that a woman with cancer would be classified as not having cancer. Lowering the threshold to 3 mm reduced the false-negative rate to about 4%.²⁰

These findings have led some researchers to question whether a single universal thickness threshold is appropriate for all patients. At minimum, they suggest that clinicians should maintain a lower threshold for biopsy in Black women with postmenopausal bleeding, especially given that Black women already face worse endometrial cancer outcomes overall.

What Happens After a Thick Lining Is Found

Finding a thick endometrium on ultrasound leads, eventually, to a tissue diagnosis. The most common first step is an endometrial biopsy, often done in the office with a thin suction device called a Pipelle. Multiple studies have found that Pipelle biopsy has excellent accuracy for detecting endometrial cancer and atypical hyperplasia, with sensitivity and specificity both near 100% for malignancy.²¹²²

Where Pipelle biopsy falls short is in detecting benign conditions that also cause thickening. Its sensitivity for endometrial polyps and hyperplasia without atypia is poor, often below 30%.²² So a “normal” Pipelle result in a woman with persistent symptoms or a persistently thick lining does not necessarily mean everything is fine. In those cases, hysteroscopy, where a tiny camera is inserted into the uterus and tissue is sampled under direct visualization, is the next step. Hysteroscopy can identify polyps, fibroids, and focal lesions that a blind suction biopsy might miss entirely.

Doppler ultrasound, which measures blood flow patterns in and around the endometrium, has also shown promise as a way to triage patients before deciding on biopsy. Studies have found that blood flow characteristics can help distinguish malignant from benign endometrial tissue, with certain indices accurately predicting cancer in women with postmenopausal bleeding.²³

Thickness Does Not Predict Stage or Grade

A natural assumption is that the thicker the lining, the more advanced or aggressive the cancer. This turns out not to be the case. A study examining whether preoperative endometrial thickness could predict tumor grade or stage in women with confirmed endometrial carcinoma found no correlation between thickness and how far the cancer had spread.²⁴ A very thick lining might harbor an early, easily treatable cancer, while a moderately thickened one could conceal an advanced tumor. This reinforces the point that the thickness measurement tells you to investigate further; it does not tell you what you will find.

Lynch Syndrome and Screening Limits

Women with Lynch syndrome, a hereditary condition that dramatically raises the risk of several cancers including endometrial cancer, present a special screening challenge. You might expect that regular ultrasound monitoring of endometrial thickness would catch cancers early in this high-risk group, but studies have produced disappointing results. Two evaluations of ultrasound screening in women with Lynch syndrome found high false-positive rates and poor efficacy. In one study, most endometrial cancers that developed in Lynch syndrome patients were caught because of symptoms, not because screening ultrasound flagged them.²⁵

There is some evidence that adding routine endometrial tissue sampling to ultrasound surveillance may improve detection. One study found that combining routine biopsies with ultrasound detected more precancerous lesions and early cancers than ultrasound alone.²⁶ Another study, however, concluded that adding standard endometrial sampling to annual ultrasound had no additional value in detecting premalignant or malignant endometrial lesions in this population.²⁷ The evidence is conflicting enough that many specialists now discuss risk-reducing hysterectomy with Lynch syndrome patients who have completed childbearing, rather than relying on imperfect screening strategies.

Treating Hyperplasia Before It Becomes Cancer

When a biopsy reveals endometrial hyperplasia rather than cancer, the treatment approach depends on whether the cells show atypical features. Simple hyperplasia without atypia can often be managed with progestin therapy, either through oral medication or a levonorgestrel-releasing intrauterine device (IUD). Both approaches can reverse the thickening and bring the lining back to a normal state, with follow-up biopsies or ultrasounds confirming that regression has occurred.²⁸ Atypical hyperplasia, which carries a higher risk of progressing to cancer, is sometimes treated the same way in women who wish to preserve fertility, but hysterectomy is generally considered the definitive treatment.

The connection between these interventions and the thickness-cancer story is practical: catching hyperplasia through thickness screening gives doctors the opportunity to intervene with reversible hormonal treatments before cancer develops. That is the real value of the measurement for most patients. It is not that a thick lining equals cancer. It is that a thick lining can be the opening of a window for prevention, especially when combined with clinical context, symptoms, and a willingness to biopsy when warranted.